Explore baxter.com

This site is intended for Healthcare Professionals only. All products may not be available in all countries. Contact your local Baxter representative.

Renal Care EMEA

Therapies

We deliver and support renal therapies across the continuum of care, including the innovative HDx.

Therapies
  • Modern PD

    Modern PD offers patients many choices. Are you ready to voice them?

  • Peritoneal Dialysis

    Peritoneal Dialysis - combined with Remote Patient Management - offers the potential to improve renal patients' clinical outcomes and increase lifestyle flexibility.

  • Hemodialysis

    Hemodialysis is the predominant therapy for end-stage kidney disease, and can be delivered through multiple therapy options.

  • HDx

    Innovative Expanded Hemodialysis (HDx) therapy is the next evolution in hemodialysis treatment.

Products

Learn more about Baxter’s key products for Renal Care – across the continuum of care.

Data & Insights

Groundbreaking research and inspirational patient stories.

  • Clinical Data

    Explore the research enabling innovative Renal Care.

  • Stories

    Patients’ journeys inspire our work and drive our commitment.

  • Resource Library

    Access resources for Baxter’s broader Renal Care portfolio.

Explore baxter.com

This site is intended for Healthcare Professionals only. All products may not be available in all countries. Contact your local Baxter representative.

Clinical Data

Clinical research lies at the heart of who we are. Baxter uses scientific evidence systematically, and transparently, to inform the development of new and state-of-the-art solutions for patients around the world. Here you can find various studies, white papers and articles concerning important topics across the wide range of therapy areas served by Baxter. 

A Focus on Clinical Research

HDx

Evaluation and comparison of polysulfone TS-UL and PMMA NF-U dialyzers versus expanded hemodialysis and postdilution hemodiafiltration.

View resource
HDx

Expanded Hemodialysis and Its Effects on Hospitalizations and Medication Usage: A Cohort Study.

View resource
HDx

Expanded hemodialysis: is anticoagulation of the dialysis circuit different from online hemodiafiltration and high-flux hemodialysis?

View resource
HDx

Medium Cut-Off Dialysis Membrane and Dietary Fiber Effects on Inflammation and Protein-Bound Uremic Toxins: A Systematic Review and Protocol for an Interventional Study.

View resource
HDx

Medium Cut-Off Membrane Can Be a New Treatment Tool in Amanita phalloides Poisoning.

View resource
HDx

Synergy of sodium thiosulphate treatment and expanded hemodialysis in the management of calciphylaxis? A case report

View resource
HDx

Updates on hemodialysis techniques with a common denominator: The personalization of the dialytic therapy.

View resource
HDx

HDx Therapy webinar, The impact of Medium Cut off (MCO) membrane in the management of Restless Leg Syndrome in HD Patients, QoL of dialysis patients and Restless Leg Syndrome – Dr. Rita Nohra, Baxter

View resource
HDx

HDx Therapy webinar, The impact of Medium Cut off (MCO) membrane in the management of Restless Leg Syndrome in HD Patients, The COREXH study and Connecting the COREXH outcomes to the MCO – Prof. Rafael Mauricio Sanabria, Baxter

View resource
HDx

HDx Therapy webinar, The impact of Medium Cut off (MCO) membrane in the management of Restless Leg Syndrome in HD Patients, The road to the COREXH study – A Quality of Life view – Prof. Juan Carlos Alarcon, Baxter

View resource
HDx

Health Economic Evaluation of the Theranova 400 Dialyzer Among Hemodialysis Patients in the United States: Results from a Randomized-Controlled Trial

View resource
HDx

Health Economic Evaluation of the Theranova 400 Dialyzer Among Hemodialysis Patients in the United States: Results from a Randomized-Controlled Trial

View resource

Are you interested in additional information about ways in which we are transforming Renal Care through Patient-Centric Innovations?

Request information here

About Us
Baxter has been a front-runner in the treatment and management of end-stage kidney disease for over 85 years. Today, our state-of-the-art solutions for both hemodialysis and peritoneal dialysis are transforming global renal care. It’s why you can rely on us to be the type of dedicated partner who understands the challenges you face throughout the continuum of care to meet the individual needs of your patients.
 

Baxter, AK 98, AN69, Artis Physio Plus, BiCart, CWP 800, Evodial, Homechoice, Nephral ST, Novaline, Polyflux, Revaclear, Sharesource, Sharesource Adequest, SoftPac, SelectBag, Theralite and Theranova are trademarks of Baxter International Inc. or its subsidiaries.

©Copyright 2024 Baxter. All rights reserved.